Hematoloxía

2016

1. A prognostic model for survival after salvage treatment with FLAG-Ida +/− gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia

   British Journal of Haematology, Vol. 174, Núm. 5, pp. 700-710

2. Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial

   Annals of Hematology, Vol. 95, Núm. 6, pp. 893-899

3. Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELD-AF and treated with vitamin K antagonists

   British Journal of Haematology, Vol. 174, Núm. 4, pp. 610-623

4. Current opinion and consensus statement regarding the diagnosis, prognosis, and treatment of patients with essential thrombocythemia: a survey of the Spanish Group of Ph-negative Myeloproliferative Neoplasms (GEMFIN) using the Delphi method

   Annals of Hematology, Vol. 95, Núm. 5, pp. 719-732

5. Efficacy and safety of long-acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery

   Haemophilia, Vol. 22, Núm. 4, pp. e259-e266

6. Efficacy and safety of pegylated full-length recombinant factor VIII with extended half-life for perioperative haemostasis in haemophilia A patients

   Haemophilia, Vol. 22, Núm. 4, pp. e251-e258

7. Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice

   European Journal of Haematology, Vol. 97, Núm. 3, pp. 297-302

8. Fiebre persistente en paciente inmunodeprimido

   Galicia Clínica, Vol. 77, Núm. 2, pp. 67-70

9. Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera

   British Journal of Haematology, Vol. 172, Núm. 5, pp. 786-793

10. Hemorrhagic cistitis after allogeneic hematopoietic cell transplantation: a retrospective study

    BONE MARROW TRANSPLANTATION, Vol. 51, Núm. Supl 1, pp. S223-S223

11. Immune tolerance induction in patients with haemophilia a and inhibitors: Effectiveness and cost analysis in an European Cohort (The ITER Study)

    Haemophilia, Vol. 22, Núm. 1, pp. 96-102

12. Investigating rare haematological disorders - A celebration of 10 years of the Sherlock Holmes symposia

    European Oncology and Haematology, Vol. 12, Núm. 1, pp. 55-61

13. Long-Term Follow-Up of a Phase II Trial of Six Cycles of Dose-Dense R-CHOP-14 for First-Line Treatment of Diffuse Large B-Cell Lymphoma in Young and Elderly Patients

    Acta Haematologica, Vol. 136, Núm. 2, pp. 76-84

14. Molecular and clinical profile of von willebrand disease in spain (PCM-EVW-ES): Proposal for a new diagnostic paradigm

    Thrombosis and Haemostasis, Vol. 115, Núm. 1, pp. 40-50

15. OPTIMIZACIÓN DE HEMOGLOBINA PERIOPERATORIA CON HIERRO CARBOXIMALTOSA EN PACIENTES DE CIRUGÍA ONCOLÓGICA DIGESTIVA. UN AÑO DE EXPERIENCIA EN EL HOSPITAL UNIVERSITARIO LUCUS AUGUSTI

    HAEMATOLOGICA, Vol. 101, Núm. Supl. 4, pp. 271

16. Practical aspects of DDAVP use in patients with von Willebrand Disease undergoing invasive procedures: A European survey

    Haemophilia, Vol. 22, Núm. 1, pp. 110-120

17. Practical aspects of factor concentrate use in patients with von Willebrand disease undergoing invasive procedures: a European survey

    Haemophilia, Vol. 22, Núm. 5, pp. 739-751

18. Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma

    European Journal of Haematology, Vol. 96, Núm. 5, pp. 532-540

19. Remission and platelet responses with romiplostim in primary immune thrombocytopenia: Final results from a phase 2 study

    British Journal of Haematology, Vol. 172, Núm. 2, pp. 262-273

20. Response to Salvage Therapy, The Main Prognosis Factor in Patients with Refractory or Relapsed Diffuse Large B-Cell Lymphoma Treated with R-ESHAP and Autologous Stem Cell Transplantation

    BONE MARROW TRANSPLANTATION, Vol. 51, Núm. Supl 1, pp. S300-S301